Resistance mutation info of drug

Drug General Information
Drug ID D0V3YT
Drug Name BOCEPREVIR
Synonyms Boceprevir; Victrelis; 394730-60-0; SCH 503034; EBP 520; UNII-89BT58KELH; SCH-503034; 89BT58KELH; CHEBI:68621; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
Drug Type Small molecular drug
Structure D0V3YT
Drug Resistance Mutations
Target Name HCV Serine protease (NS3) Target Info
Gene Name NS3
Uniprot ID POLG_HCVJA(1027-1657)
Species Hepatitis C virus genotype 1b
Reference Sequence APITAYSQQTRGLLGCIITSLTGRDKNQVDGEVQVLSTATQSFLATCVNGVCWTVYHGAG
SKTLAGPKGPITQMYTNVDQDLVGWPAPPGARSMTPCTCGSSDLYLVTRHADVVPVRRRG
DSRGSLLSPRPISYLKGSSGGPLLCPSGHVVGIFRAAVCTRGVAKAVDFIPVESMETTMR
SPVFTDNSSPPAVPQTFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGA
YMSKAHGIEPNIRTGVRTITTGGPITYSTYCKFLADGGCSGGAYDIIICDECHSTDSTTI
LGIGTVLDQAETAGARLVVLATATPPGSITVPHPNIEEVALSNTGEIPFYGKAIPIEAIK
GGRHLIFCHSKKKCDELAAKLTGLGLNAVAYYRGLDVSVIPTSGDVVVVATDALMTGFTG
DFDSVIDCNTCVTQTVDFSLDPTFTIETTTLPQDAVSRAQRRGRTGRGRSGIYRFVTPGE
RPSGMFDSSVLCECYDAGCAWYELTPAETSVRLRAYLNTPGLPVCQDHLEFWESVFTGLT
HIDAHFLSQTKQAGDNLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLY
RLGAVQNEVTLTHPITKYIMACMSADLEVVT [Hepatitis C virus genotype
1b]
Targeted Disease HCV infection
Drug Resistance Mutations
Mutation info Missense: A156S [1]
Mutation Frequency 31% of the patiens
Level of Resistance Confer 24 fold resistance
Mutation info Missense: A156T [1]
Mutation Frequency 12% of the patiens
Level of Resistance Confer 128 fold resistance
Mutation info Missense: F43S [1]
Level of Resistance Confer 3.5 fold resistance
Mutation info Missense: R155K [1]
Level of Resistance Confer 3.6 fold resistance
Mutation info Missense: T54A [1]
Mutation Frequency 31% of the patiens
Level of Resistance Confer 6.7 fold resistance
Mutation info Missense: V170A [1]
Mutation Frequency 25% of the patients
Level of Resistance Confer 19 fold resistance
Mutation info Missense: V36M [1]
Level of Resistance Confer 2.9 fold resistance
References
REF 1 Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 2006 Jun;70(2):28-38.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.